Published in J Oncol Pharm Pract on March 01, 2005
[Not Available]. Can J Hosp Pharm (2010) 0.92
Computerized detection and analysis of cancer chemotherapy-induced emesis in a small animal model, musk shrew. J Neurosci Methods (2011) 0.86
Minimising treatment-associated risks in systemic cancer therapy. Pharm World Sci (2007) 0.80
The economics of medicines optimization: policy developments, remaining challenges and research priorities. Br Med Bull (2014) 0.75
Cutaneous metastatic rectal carcinoma masquerading as herpes zoster. South Med J (2011) 1.11
Drug monographs: dabrafenib and trametinib. Hosp Pharm (2013) 0.82
Drug monographs: bosutinib and regorafenib. Hosp Pharm (2013) 0.76
Cost savings realized by use of the PhaSeal(®) closed-system transfer device for preparation of antineoplastic agents. J Oncol Pharm Pract (2013) 0.76
Drug monographs: ibrutinib and ramucirumab. Hosp Pharm (2014) 0.75
Pentostatin, Cyclophosphamide and Rituximab (PCR) Regimen. Hosp Pharm (2016) 0.75
Alectinib, Ceritinib, Elotuzumab, and Venetoclax. Hosp Pharm (2016) 0.75
Arsenic Trioxide and Tretinoin (AsO/ATRA) for Acute Promyelocytic Leukemia (APL). Hosp Pharm (2016) 0.75
Procarbazine, Lomustine, and Vincristine (PCV) Regimen for Central Nervous System Tumors. Hosp Pharm (2017) 0.75
Lenalidomide, Bortezomib, and Dexamethasone (RVD) Regimen for Multiple Myeloma. Hosp Pharm (2017) 0.75
Drug Monographs: Atezolizumab and Everolimus. Hosp Pharm (2016) 0.75
Drug Monographs: Olaratumab and Rucaparib. Hosp Pharm (2017) 0.75
Lenvatinib and Palbociclib. Hosp Pharm (2015) 0.75
Ado-trastuzumab emtansine and radium 223 dichloride. Hosp Pharm (2013) 0.75
Drug monographs: pomalidomide and ponatinib. Hosp Pharm (2013) 0.75
Carboplatin and Liposomal Doxorubicin for Ovarian Cancer. Hosp Pharm (2016) 0.75
Idelalisib and Rituximab Regimen. Hosp Pharm (2017) 0.75
Drug Monographs: Ixazomib and Necitumumab. Hosp Pharm (2016) 0.75
Nivolumab and Olaparib. Hosp Pharm (2015) 0.75
Cabazitaxel and Prednisone Regimen for Prostate Cancer. Hosp Pharm (2015) 0.75
Drug Monographs: Daratumumab and Osimertinib. Hosp Pharm (2016) 0.75
Capecitabine and Gemcitabine (CapGem, CG, GemCap) for Advanced Pancreatic and Biliary Tract Cancer. Hosp Pharm (2014) 0.75
Survey of carboplatin dosing strategies in oncology practices. J Am Pharm Assoc (2003) (2013) 0.75